copenlu/druid huggingface dataset:
Claim: Switzerland stops COVID-19 vaccines due to safety concerns (Anthony Hinton, 2023-04-19)
Evidence (2021-11-26): Bern, 26.11.2021 - In view of the significant rise in cases in Switzerland, the Federal Office of Public Health FOPH and the Federal Commission for Vaccination (FCV) recommend a booster vaccination for the general population, including for under-65s. This is in line with the authorisation decision taken by Swissmedic, the Agency for Therapeutic Products. The booster vaccination is intended to strengthen individual protection against infection and slow down the transmission and spread of the virus in the current epidemiological situation. So far, more than 350,000 people have received a booster vaccination. These are over-65s and younger persons who are at the highest risk of experiencing serious illness. These groups will continue to have priority access to a booster vaccination. [...] In the current epidemic situation, the FOPH and FCV recommendation that all young people aged 16 and over and all adults should receive a booster vaccination is also aimed at helping prevent the healthcare system from becoming overloaded. The recommendation is based on Swissmedic’s authorisation extension. This permits a booster vaccination with the two mRNA vaccines, using Pfizer for people aged over 16 and Moderna for those aged over 18. [...] Switzerland has sufficient vaccine of both mRNA products to offer vaccinations in 2021 and 2022 to all those recommended for a booster vaccination and to all those who have not yet been vaccinated.
Claim: Switzerland stops COVID-19 vaccines due to safety concerns (Anthony Hinton, 2023-04-19)
Evidence (2021-05-07): Bern, 07.05.2021 - 1,953 reports of suspected adverse reactions to COVID-19 vaccines in Switzerland evaluated: As at 4 May 2021, Swissmedic has evaluated 1,953 reports of suspected adverse drug reactions (ADR) to COVID-19 vaccinations in Switzerland. The reports corroborate the side effects profile identified during the authorisation studies and described in the medicinal product information, and do not alter the positive ratio of benefits to risks of the two mRNA vaccines used. [...] The reports of adverse reactions received and analysed to date do not alter the positive benefit-risk profile of the COVID-19 vaccines used in Switzerland. Any pointers to as yet unknown safety problems based on reports from within Switzerland or from abroad will be thoroughly investigated. Thus, for example, some very rare reports from around the world of immune thrombocytopenia (ITP) or inflammation of the heart muscle (myocarditis) are being discussed and analysed further. In evaluating the safety aspects of the COVID-19 vaccines, Swissmedic is also in close and regular contact with other international drug regulatory agencies. As soon as valid findings are available on possible risks, we will provide information about these and about any measures that can be taken to alleviate them. The reports now provide us with a clearer picture of the vaccines’ safety in daily use. This largely confirms their known side effects profile. Known side effects of COVID-19 vaccines are listed in the continually updated medicinal product information texts published on www.swissmedicinfo.ch.
Claim: Switzerland stops COVID-19 vaccines due to safety concerns (Anthony Hinton, 2023-04-19)
Evidence (2020-12-21): Reports of suspected adverse reactions to COVID-19 vaccines in Switzerland – update 24.09.2021 [...] The reports of adverse reactions received and analysed to date do not alter the positive benefit-risk profile of the COVID-19 vaccines used in Switzerland. This largely confirms their known side effects profile. Known side effects of COVID-19 vaccines are listed in the continually updated medicinal product information texts published on www.swissmedicinfo.ch. [...] You can find the latest report on suspected adverse reactions to COVID-19 vaccines in Switzerland at the following permalink: www.swissmedic.ch/covid-19-vaccines-safety-update-en
Claim: Switzerland stops COVID-19 vaccines due to safety concerns (Anthony Hinton, 2023-04-19)
Evidence (2021-01-12): Second COVID-19 vaccine approved for Switzerland Bern, 12.01.2021 - On 12 January 2021 Swissmedic, the Swiss agency for the authorisation and supervision of therapeutic products, approved the second COVID-19 vaccination for the Swiss market. The vaccine from Moderna, of which the federal government has ordered around 7.5 million doses, is suitable for adults from age 18. In the next few days an initial delivery of 200,000 doses will be made to the Armed Forces Pharmacy, which will distribute the vaccine to the cantons. Together with the Pfizer/BioNTech vaccine approved by Swissmedic on 19 December 2020, around half a million doses of vaccine are available in Switzerland in January. The first priority will be to vaccinate especially vulnerable people. The COVID-19 vaccine from Moderna is the second to be approved by Swissmedic. On the basis of the safety, efficacy and quality data the vaccine is suitable without age restrictions for all adults aged 18 and over. The federal government has ordered 7.5 million doses from Moderna.
Claim: Switzerland stops COVID-19 vaccines due to safety concerns (Anthony Hinton, 2023-04-19)
Evidence (2024-09-09): From autumn 2024 onwards, COVID-19 vaccination is recommended in autumn/winter for persons at an increased risk of developing a severe case of the illness (including pregnant persons). COVID-19 vaccination is not recommended for any other persons. Almost everyone in Switzerland has come into contact with the coronavirus by now, meaning that their immune system has already had to respond to the virus. The coronavirus variants currently circulating also tend to cause only mild cases of COVID-19 among persons without any risk factors. As a result of the greater contacts that people are likely to have in enclosed spaces, the coronavirus may well spread more again in the coming winter season. And this in turn may increase the likelihood of contracting COVID-19.
Claim: Switzerland stops COVID-19 vaccines due to safety concerns (Anthony Hinton, 2023-04-19)
Evidence (2024-05-16): COVID-19 vaccination in Switzerland is an ongoing immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country. [...] - ^ "Swissmedic grants authorisation for the first COVID-19 vaccine in Switzerland" (Press release). Swiss Agency for Therapeutic Products (Swissmedic). December 19, 2020. Archived from the original on January 10, 2021. Retrieved December 19, 2020. [...] - ^ "Swissmedic grants authorisation for the COVID-19 vaccine from Moderna". Swissmedic (Press release). January 12, 2020. Archived from the original on February 11, 2021. Retrieved January 12, 2020.
Claim: Switzerland stops COVID-19 vaccines due to safety concerns (Anthony Hinton, 2023-04-19)
Evidence (2021-05-21): Bern, 21.05.2021 - 2,269 reports of suspected adverse reactions to COVID-19 vaccines in Switzerland evaluated: Up to 18 May 2021, Swissmedic evaluated 2,269 reports on suspected adverse drug reactions (ADR) to COVID-19 vaccinations in Switzerland. The reports corroborate the side effects profile identified during the authorisation studies and described in the medicinal product information, and do not alter the positive ratio of benefits to risks of the two mRNA vaccines used. [...] The reports of adverse reactions received and analysed to date do not alter the positive benefit-risk profile of the COVID-19 vaccines used in Switzerland. Any pointers to as yet unknown safety problems based on reports from within Switzerland or from abroad will be thoroughly investigated. Thus, for example, some very rare reports from around the world of immune thrombocytopenia (ITP) or inflammation of the heart muscle (myocarditis) are being analysed further. In evaluating the safety aspects of the COVID-19 vaccines, Swissmedic is also in close and regular contact with other international drug regulatory agencies. As soon as valid findings are available on possible risks, we will provide information about these and about any measures that can be taken to alleviate them.
Claim: Switzerland stops COVID-19 vaccines due to safety concerns (Anthony Hinton, 2023-04-19)
Evidence (2023-04-17): The claim: Switzerland banned COVID-19 vaccine [...] "Switzerland Bans the COVID Vaccines," reads the article's headline. [...] Tesia Williams, a Johnson & Johnson spokesperson, told USA TODAY the company has decided to stop distributing its COVID-19 vaccine in Switzerland due to declining need and the availability of other vaccines.
Claim: Switzerland stops COVID-19 vaccines due to safety concerns (Anthony Hinton, 2023-04-19)
Evidence (2023-02-24): Reports of suspected adverse reactions to the COVID-19 vaccines in Switzerland [...] Since the concluding standard report on adverse reactions to the COVID-19 vaccines in Switzerland was published at the end of February 2023, an additional 720 suspicion reports have been evaluated. For an estimated 17 million vaccine doses1 administered to date in Switzerland, Swissmedic received a total of 17,575 reports of suspected reactions in connection with the COVID-19 vaccines up to 30 June 2024. [...] The COVID-19 vaccines are also listed in the annual vaccinovigilance report on the safety of vaccines used in Switzerland. As soon as new, relevant findings are available, Swissmedic will provide information via the usual channels (drug safety communications, Swissmedic Vigilance News, DHPC).
Claim: Switzerland stops COVID-19 vaccines due to safety concerns (Anthony Hinton, 2023-04-19)
Evidence (2021-04-09): Side effects of COVID-19 vaccines in Switzerland – update Bern, 09.04.2021 - 1174 reports of suspected adverse reactions to COVID-19 vaccines in Switzerland evaluated: As at 6 April 2021, Swissmedic, in collaboration with the regional pharmacovigilance centres (in particular with the Ticino EOC reference centre), has evaluated 1174 reports of suspected adverse drug reactions (ADR) to COVID-19 vaccinations in Switzerland. The reports corroborate the side effects profile identified during the authorisation studies and described in the medicinal product information. They do not alter the positive ratio of benefits to risks of the vaccines used. [...] The reports of adverse reactions received and analysed to date do not change the positive benefit-risk profile of the COVID-19 vaccines. The reports now provide us with a clearer picture of the vaccines’ safety in daily use. This largely confirms their known side effects profile. Known side effects of COVID-19 vaccines are listed in the continually updated medicinal product information texts published on www.swissmedicinfo.ch.
Claim: Switzerland stops COVID-19 vaccines due to safety concerns (Anthony Hinton, 2023-04-19)
Evidence (2021-12-17): At its meeting, the Federal Council also discussed the procurement of COVID-19 vaccines. It is ordering 7 million doses of both the Moderna and Pfizer/BioNTech vaccines for the second half of 2022. It had already secured 7 million doses of each for the first half of the year. This means that a total of around 34 million vaccine doses will be available in 2022. There is therefore a sufficient supply of vaccines for all those wishing to be vaccinated in 2022. This also applies should the pandemic be driven by an immune-evasive variant and if additional doses have to be administered. Under the current agreements, Switzerland always receives the latest available vaccine variant from the respective manufacturer, provided it has been approved by Swissmedic. From the outset, Switzerland has been committed to ensuring that as many people as possible worldwide have access to safe and effective COVID-19 vaccines as part of the global pandemic response. On 30 June, the Federal Council decided to donate 4 million COVID-19 vaccine doses. A possible transfer of further doses to the COVAX initiative will be considered at a later date.
Claim: Switzerland stops COVID-19 vaccines due to safety concerns (Anthony Hinton, 2023-04-19)
Evidence (2024-09-30): First Swiss damages awarded for Covid vaccine side-effects [...] Listening: First Swiss damages awarded for Covid vaccine side-effects For the first time in Switzerland, a person has received financial compensation for coronavirus vaccine damage. Compensation of CHF12,500 and damages of CHF1,360 have been awarded.
Claim: Switzerland stops COVID-19 vaccines due to safety concerns (Anthony Hinton, 2023-04-19)
Evidence (2020-12-21): Side effects of COVID-19 vaccines in Switzerland – update 04.06.2021 [...] In evaluating the safety aspects of the COVID-19 vaccines, Swissmedic is also in close and regular contact with other international drug regulatory agencies. As soon as valid findings are available on possible risks, we will provide information about these and about any measures that can be taken to alleviate them. The reports now provide us with a clearer picture of the vaccines’ safety in daily use. The reports of adverse reactions received and analysed to date do not alter the positive benefit-risk profile of the COVID-19 vaccines used in Switzerland. This largely confirms their known side effects profile. Known side effects of COVID-19 vaccines are listed in the continually updated medicinal product information texts published on www.swissmedicinfo.ch.
Claim: Switzerland stops COVID-19 vaccines due to safety concerns (Anthony Hinton, 2023-04-19)
Evidence (2020-12-21): Reports of suspected adverse reactions to COVID-19 vaccines in Switzerland – update 29 24.02.2023 [...] The reports of adverse reactions received and analysed to date do not alter the positive benefit-risk profile of the COVID-19 vaccines used in Switzerland. This largely confirms their known side effects profile. Known side effects of COVID-19 vaccines are listed in the continually updated medicinal product information texts published on www.swissmedicinfo.ch. [...] For some time now, Swissmedic has been receiving far fewer reports of suspected adverse reactions than when vaccination first started and will therefore provisionally cease publishing regular updates on reported adverse reactions to COVID-19 vaccines in their current form. However, the Agency will continue to monitor COVID-19 vaccines closely and new information on risks and safety signals will be communicated via the usual channels (website, DHPCs).
Claim: Switzerland stops COVID-19 vaccines due to safety concerns (Anthony Hinton, 2023-04-19)
Evidence (2023-03-08): The Commission on Human Medicine (CHM) has advised that given the end of the Autumn 2022 booster campaign and the stable safety profile of the COVID-19 vaccines, the MHRA should transition to routine data publication and communication of safety concerns for COVID-19 vaccines. This report is therefore the last regular publication of the Summary of Yellow Card reporting for COVID-19 vaccines. [...] All vaccines and medicines have some side effects although not everybody gets them. These side effects need to be continuously balanced against the expected benefits in preventing illness. As part of the MHRA’s responsibility to ensure that the benefits of the COVID-19 vaccines used in the UK continue to outweigh the risks, the MHRA is closely monitoring the bivalent mRNA vaccines and COVID-19 vaccine Novavax using the proactive pharmacovigilance surveillance strategy in place for the initial vaccine rollout. We also work closely with our public health partners in reviewing the effectiveness and impact of the vaccines to ensure the benefits continue to outweigh any possible side effects. Our ongoing review of suspected adverse events following the launch of the National Autumn 2022 booster campaign has not revealed any new safety concerns. [...] The Commission on Human Medicines (CHM) advises ministers on the safety, efficacy and quality of medicinal products. For COVID-19 vaccines, the CHM has a COVID-19 Vaccines Safety Surveillance Methodologies Expert Working Group and a COVID-19 Vaccines Benefit Risk Expert Working Group.
Claim: Switzerland stops COVID-19 vaccines due to safety concerns (Anthony Hinton, 2023-04-19)
Evidence (2024-07-23): During the 2009 H1N1 pandemic, solid organ transplant (SOT) recipients in Switzerland received two doses of an AS03-adjuvanted influenza vaccine (Pandemrix). The authors compared the safety and immunogenicity of two doses of AS03-adjuvanted vaccine in more than 200 SOT recipients (heart, lung, liver, kidney, pancreas/islet of Langerhans) to one dose in healthy family controls. Adverse reactions occurred less frequently in the SOT group and SOT graft function remained unaffected.
Claim: Switzerland stops COVID-19 vaccines due to safety concerns (Anthony Hinton, 2023-04-19)
Evidence (2024-10-02): FDA amended EUAs of Moderna and Pfizer-BioNTech COVID-19 bivalent mRNA vaccines. Bivalent vaccines were to be used for all doses given to individuals 6 months and older. Monovalent COVID-19 vaccines were no longer authorized for use in the United States. April 18, 2023 [...] CDC and FDA lifted the recommended pause of use of the Johnson & Johnson (Janssen) COVID-19 vaccine in the United States after a review by ACIP. The use of the Janssen vaccine should resume. EUA fact sheets for Johnson & Johnson (Janssen) COVID-19 vaccine revised. April 23, 2021 CDC and FDA recommended a pause in the use of the Janssen (Johnson & Johnson) COVID-19 vaccine in the United States out of an abundance of caution. A CDC Health Alert Network (HAN) was issued with recommendations. April 13, 2021
Claim: Switzerland stops COVID-19 vaccines due to safety concerns (Anthony Hinton, 2023-04-19)
Evidence (2024-02-20): - The Federal Office of Public Health (FOPH) and the Federal Commission for Vaccinations (FCV) recommend that vulnerable people get vaccinated against Covid-19 this autumn/winter. This includes people over 65, those aged 16 and over with a pre-existing illness or Down syndrome, and pregnant women with a pre-existing illness. The coronavirus continues to circulate and can cause a severe form of Covid-19 in vulnerable people, they said on September 11. No official vaccination recommendations are made for other groups of people. In the absence of risk factors, the probability of developing a serious form of the disease is low, FOPH says. However, vaccination is still possible against payment. [...] - Switzerland will no longer issue or verify Covid-19 certificates from September 2023, the government said on August 16. The system and its technical infrastructure will cease to operate at the end of August. This decision is linked to the expiration of the legal basis for the European Union’s digital Covid certificate at the end of June and in view of the stable epidemiological situation, the authorities said. [...] Switzerland will no longer issue or verify Covid-19 certificates from September 2023, the government said on August 16. The system and its technical infrastructure will cease to operate at the end of August. This decision is linked to the expiration of the legal basis for the European Union’s digital Covid certificate at the end of June and in view of the stable epidemiological situation, the authorities said.
Claim: Switzerland stops COVID-19 vaccines due to safety concerns (Anthony Hinton, 2023-04-19)
Evidence (2020-11-24): To reduce the spread of SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19) and its associated impacts on health and society, COVID-19 vaccines are essential. The U.S. government is working to produce and deliver safe and effective COVID-19 vaccines for the entire U.S. population. The Advisory Committee on Immunization Practices (ACIP)* has broadly outlined its approach for developing recommendations for the use of each COVID-19 vaccine authorized or approved by the Food and Drug Administration (FDA) for Emergency Use Authorization or licensure (1). ACIP’s recommendation process includes an explicit and transparent evidence-based method for assessing a vaccine’s safety and efficacy as well as consideration of other factors, including implementation (2). Because the initial supply of vaccine will likely be limited, ACIP will also recommend which groups should receive the earliest allocations of vaccine. The ACIP COVID-19 Vaccines Work Group and consultants with expertise in ethics and health equity considered external expert committee reports and published literature and deliberated the ethical issues associated with COVID-19 vaccine allocation decisions.
Claim: Switzerland stops COVID-19 vaccines due to safety concerns (Anthony Hinton, 2023-04-19)
Evidence (2022-08-01): Franklin University Switzerland strongly encourages the entire Franklin community to complete their COVID vaccinations. While we understand this might not be possible for everyone depending on your location and personal situation, we encourage you to do what you can to keep our community safe. We are working hard to put the pandemic behind us and create a 2023-2024 campus environment that is both safe and vibrant. [...] Below are frequently asked questions about the COVID vaccine to help students better understand the situation at Franklin and in Switzerland. We will update these answers and information as conditions changes, but please keep in mind that our experience with COVID-19 has taught us that things can change quickly. [...] The most important step is to complete your COVID vaccinations before coming to campus if you can. The entire Franklin community is asked to stay informed and to follow the current Franklin and Swiss guidelines to protect the Franklin community. These policies and guidelines may change as the epidemiological situation shifts. We ask students to recognize their social responsibility towards their community to stop the spread of COVID-19 by following campus guidelines and being held accountable for their actions.
Claim: Switzerland stops COVID-19 vaccines due to safety concerns (Anthony Hinton, 2023-04-19)
Evidence (2020-03-20): On June 15, COVID-19 related entry restrictions were lifted for all EU/EFTA states and the United Kingdom. On July 6, the restrictions on the admission of workers from some third countries (i.e. outside the EU and EFTA) were lifted. On July 1, following a similar decision by the EU, Switzerland decided to reopen the borders to 13 non-EU countries and 5 EU countries outside the Schengen area from July 20. The lists of countries with which Switzerland has open borders and of high-risk locations with mandatory quarantine for arrivals to Switzerland are periodically reviewed. In view of the increasing volume of people traveling and the rising number of new infections since mid-June, the FC decided on July 1 to make masks compulsory on all public transport from July 6 and on all flights taking off or landing in Switzerland from August 15. Some cantons reintroduced additional restrictions, such as limiting public events to 100 people. On September 18, Switzerland confirmed its participation in the COVID-19 Vaccine Global Access Facility (COVAX) initiative, a procurement mechanism joined by countries around the world to ensure a fair distribution of COVID-19 vaccines globally.